计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
rp175336-500μg |
500μg |
期货 ![]() |
| |
rp175336-1mg |
1mg |
期货 ![]() |
|
产品名称 | tumour necrosis factor shed form, 肿瘤坏死因子受体 1 |
---|---|
别名 | 肿瘤坏死因子脱落型 |
英文别名 | cachectin | necrosin | TNF alpha soluble form | TNF shed form | tumor necrosis factor soluble form |
规格或纯度 | Moligand™ |
作用机制 | 肿瘤坏死因子受体 1 |
CAS编号和信息 | rp175336 |
---|
1. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.. Pharmacol Ther, 117 (2): (244-79). [PMID:18155297] [10.1021/op500134e] |
2. Crowe JS, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Clare S, Harcourt K, Reckless J, MacDonald TT, Ray KP et al.. (2018) Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.. Sci Rep, 8 (1): (4941). [PMID:29563546] [10.1021/op500134e] |
3. Gahring LC, Carlson NG, Kulmar RA, Rogers SW. (1996) Neuronal expression of tumor necrosis factor alpha in the murine brain.. Neuroimmunomodulation, 3 (5): (289-303). [PMID:9218250] [10.1021/op500134e] |